2024
Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial
Chey W, Mégraud F, Laine L, Smith N, Leifke E, Hunt B, Howden C. Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial. JGH Open 2024, 8: e70044. PMID: 39554983, PMCID: PMC11567116, DOI: 10.1002/jgh3.70044.Peer-Reviewed Original Research
2022
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022, 163: 608-619. PMID: 35679950, DOI: 10.1053/j.gastro.2022.05.055.Peer-Reviewed Original ResearchConceptsEradication rateHelicobacter pylori infectionTriple therapyDual therapyPylori infectionProton pump inhibitor-based triple therapyTreatment-emergent adverse eventsInhibitor-based triple therapyPotassium-competitive acid blockerEfficacy of vonoprazanH pylori eradicationPhase 3 trialOverall study populationAmoxicillin-resistant strainsClarithromycin-resistant strainsH pylori infectionTreatment-naïve adultsPylori eradicationAdverse eventsSecondary outcomesPrimary outcomeStandard treatmentClinical trialsStudy populationAcid blocker
2003
Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistanceIs it time for quadruple therapy to be first line?
Laine L. Is it time for quadruple therapy to be first line? 2003, 347-351. DOI: 10.1007/978-94-017-1763-2_36.ChaptersProton pump inhibitorsTriple therapyEradication ratePylori infectionCombination of PPIBismuth-based triple therapyPooled eradication ratesH. pylori infectionHelicobacter pylori infectionQuadruple therapyEarly therapyCurrent therapiesPump inhibitorsSeparate medicationsTherapyFirst lineInfectionStudies2–4Medications
2002
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial
Laine L, Dhir V. Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Alimentary Pharmacology & Therapeutics 2002, 16: 1143-1148. PMID: 12030957, DOI: 10.1046/j.1365-2036.2002.01267.x.Peer-Reviewed Original ResearchMeSH Keywords2-PyridinylmethylsulfinylbenzimidazolesAdultAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsBreath TestsClarithromycinDrug Therapy, CombinationDyspepsiaFemaleGastroesophageal RefluxHelicobacter InfectionsHumansLansoprazoleMaleMiddle AgedOmeprazolePenicillinsProspective StudiesQuality of LifeUreaConceptsGastro-oesophageal reflux diseaseQuality of lifeH. pylori therapyPylori therapyReflux diseaseH. pyloriSymptomatic gastro-oesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyPopulation of patientsEnd of therapyUrea breath testReflux symptomsPylori eradicationTriple therapyProspective trialEndoscopic biopsyPrimary complaintProspective studyLife QuestionnaireBreath testPatientsTherapyMonthsSymptoms
2000
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials
Laine L, Fennerty M, Osato M, Sugg J, Suchower L, Probst P, Levine J. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. The American Journal Of Gastroenterology 2000, 95: ajg20001583. PMID: 11151867, DOI: 10.1111/j.1572-0241.2000.03349.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmoxicillinClarithromycinDouble-Blind MethodDrug Administration ScheduleDrug Resistance, MicrobialDrug Therapy, CombinationDuodenal UlcerEsomeprazoleFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedPenicillin ResistancePenicillinsProspective StudiesProtein Synthesis InhibitorsProton Pump InhibitorsConceptsEradication rateClarithromycin resistanceDaily esomeprazoleTriple therapyDuodenal ulcerProton pump inhibitor-based triple therapyTen-day triple therapyHelicobacter pylori eradication therapyEmergent resistanceH. pylori-positive patientsInhibitor-based triple therapyDouble-blind trialTreat eradication ratesCompletion of therapyPylori eradication therapyPylori-positive patientsSeparate randomized trialsAntibiotic resistanceDaily amoxicillinUS multicenterEradication therapyRandomized trialsHelicobacter pyloriTherapyEsomeprazoleEndoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori
Laine L, Sugg J, Suchower L, Neil G. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. Gastrointestinal Endoscopy 2000, 51: 664-669. PMID: 10840297, DOI: 10.1067/mge.2000.105776.Peer-Reviewed Original ResearchConceptsTriple therapyH pylori infectionBody biopsyAntral biopsiesHistologic examinationPylori infectionBiopsy testsDiagnostic yieldProton pump inhibitor-based triple therapyMulticenter double-blind trialInhibitor-based triple therapyDouble-blind trialPost-treatment sensitivityTriple therapy groupDual antibiotic therapyH pylori statusRapid urease testEndoscopic biopsy testsPost-treatment diagnosisHelicobacter pylori diagnosisPretreatment sensitivityEradication therapyUntreated patientsAntibiotic therapyDual therapy
1999
Once-daily therapy for H. pylori infection: a randomized comparison of four regimens
Laine L, Estrada R, Trujillo M, Cheybani K, Yeramian P, Smith S, Neil G. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. The American Journal Of Gastroenterology 1999, 94: 962. PMID: 10201465, DOI: 10.1111/j.1572-0241.1999.995_r.x.Peer-Reviewed Original ResearchConceptsH. pylori infectionEradication ratePylori infectionExtended-release formulationDaily therapyBreath testDaily triple therapyHigh-dose omeprazoleTreat eradication ratesCompletion of therapyHelicobacter pylori infectionRepeat breath testStudy medicationTriple therapyEndoscopic biopsyRandomized comparisonLack of complianceTherapyPilot studyInfectionFurther studiesClarithromycinOmamDaysSubjects
1998
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials
Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. The American Journal Of Gastroenterology 1998, 93: ajg1998488. PMID: 9820381, DOI: 10.1111/j.1572-0241.1998.00602.x.Peer-Reviewed Original ResearchConceptsDuodenal ulcer diseaseTriple therapyEradication rateUlcer diseaseH. pylori-infected patientsDaily triple therapyDays of omeprazoleDuodenal ulcer historyProtocol cure ratesProtocol eradication ratesTreat eradication ratesHelicobacter pylori eradicationPylori-infected patientsOAC patientsStudy medicationTreat populationUlcer historyPylori eradicationStudy drugAdverse eventsTwice DailyControlled TrialsDuodenal ulcerCure ratePatientsTwice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. Pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. Trials
Laine L, Suchower L, Connors A, Frantz J, Neil G. Twice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. Pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. Trials. Gastroenterology 1998, 114: a193. DOI: 10.1016/s0016-5085(98)80787-7.Peer-Reviewed Original Research